The Prolonged Activation of the p65 Subunit of the NF-Kappa-B Nuclear Factor Sustains the Persistent Effect of Advanced Glycation End Products on Inflammatory Sensitization in Macrophages

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorASSIS, Sayonara Ivana Santos de
dc.contributor.authorAMENDOLA, Leonardo Szalo
dc.contributor.authorOKAMOTO, Maristela Mitiko
dc.contributor.authorFERREIRA, Guilherme da Silva
dc.contributor.authorIBORRA, Rodrigo Tallada
dc.contributor.authorSANTOS, Danielle Ribeiro
dc.contributor.authorSANTANA, Monique de Fatima Mello
dc.contributor.authorSANTANA, Kelly Gomes
dc.contributor.authorCORREA-GIANNELLA, Maria Lucia
dc.contributor.authorBARBEIRO, Denise Frediani
dc.contributor.authorSORIANO, Francisco Garcia
dc.contributor.authorMACHADO, Ubiratan Fabres
dc.contributor.authorPASSARELLI, Marisa
dc.date.accessioned2024-04-05T19:29:04Z
dc.date.available2024-04-05T19:29:04Z
dc.date.issued2024
dc.description.abstractAdvanced glycation end products (AGEs) prime macrophages for lipopolysaccharide (LPS)-induced inflammation. We investigated the persistence of cellular AGE-sensitization to LPS, considering the nuclear content of p50 and p65 nuclear factor kappa B (NFKB) subunits and the expression of inflammatory genes. Macrophages treated with control (C) or AGE-albumin were rested for varying intervals in medium alone before being incubated with LPS. Comparisons were made using one-way ANOVA or Student t-test (n = 6). AGE-albumin primed macrophages for increased responsiveness to LPS, resulting in elevated levels of TNF, IL-6, and IL-1beta (1.5%, 9.4%, and 5.6%, respectively), compared to C-albumin. TNF, IL-6, and IL-1 beta secretion persisted for up to 24 h even after the removal of AGE-albumin (area under the curve greater by 1.6, 16, and 5.2 times, respectively). The expressions of Il6 and RelA were higher 8 h after albumin removal, and Il6 and Abca1 were higher 24 h after albumin removal. The nuclear content of p50 remained similar, but p65 showed a sustained increase (2.9 times) for up to 24 h in AGE-albumin-treated cells. The prolonged activation of the p65 subunit of NFKB contributes to the persistent effect of AGEs on macrophage inflammatory priming, which could be targeted for therapies to prevent complications based on the AGE-RAGE-NFKB axis.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexScopus
dc.description.indexDimensions
dc.description.indexWoS
dc.description.sponsorshipFundao de Amparo Pesquisa do Estado de So Paulo, FAPESP
dc.identifier.citationINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.25, n.5, article ID 2713, 16p, 2024
dc.identifier.doi10.3390/ijms25052713
dc.identifier.eissn1422-0067
dc.identifier.issn1661-6596
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/58797
dc.language.isoeng
dc.publisherMDPIeng
dc.relation.ispartofInternational Journal of Molecular Sciences
dc.rightsopenAccesseng
dc.rights.holderCopyright MDPIeng
dc.subjectadvanced glycation end productseng
dc.subjectNFKBeng
dc.subjectRAGEeng
dc.subjecttoll-like receptoreng
dc.subjectlipopolysaccharideeng
dc.subjectinflammationeng
dc.subject.othermetabolic-controleng
dc.subject.otheroxidative stresseng
dc.subject.othergene-expressioneng
dc.subject.otherreinstitutioneng
dc.subject.otherdegradationeng
dc.subject.otherproteinseng
dc.subject.otherreceptoreng
dc.subject.wosBiochemistry & Molecular Biologyeng
dc.subject.wosChemistry, Multidisciplinaryeng
dc.titleThe Prolonged Activation of the p65 Subunit of the NF-Kappa-B Nuclear Factor Sustains the Persistent Effect of Advanced Glycation End Products on Inflammatory Sensitization in Macrophageseng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalOKAMOTO, Maristela Mitiko:Univ Sao Paulo, Inst Biomed Sci, Dept Physiol & Biophys, BR-05508000 Sao Paulo, Brazil
hcfmusp.author.externalIBORRA, Rodrigo Tallada:Univ Sao Judas Tadeu, Ciencias Biol & Saude, BR-03408050 Sao Paulo, Brazil
hcfmusp.author.externalMACHADO, Ubiratan Fabres:Univ Sao Paulo, Inst Biomed Sci, Dept Physiol & Biophys, BR-05508000 Sao Paulo, Brazil
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcSAYONARA IVANA SANTOS DE ASSIS
hcfmusp.contributor.author-fmusphcLEONARDO SZALO AMENDOLA
hcfmusp.contributor.author-fmusphcGUILHERME DA SILVA FERREIRA
hcfmusp.contributor.author-fmusphcDANIELLE RIBEIRO SANTOS
hcfmusp.contributor.author-fmusphcMONIQUE DE FATIMA MELLO SANTANA
hcfmusp.contributor.author-fmusphcKELLY GOMES SANTANA
hcfmusp.contributor.author-fmusphcMARIA LUCIA CARDILLO CORREA GIANNELLA
hcfmusp.contributor.author-fmusphcDENISE FREDIANI BARBEIRO
hcfmusp.contributor.author-fmusphcFRANCISCO GARCIA SORIANO
hcfmusp.contributor.author-fmusphcMARISA PASSARELLI
hcfmusp.description.articlenumber2713
hcfmusp.description.issue5
hcfmusp.description.volume25
hcfmusp.origemWOS
hcfmusp.origem.dimensionspub.1169324893
hcfmusp.origem.pubmed38473959
hcfmusp.origem.scopus2-s2.0-85187448281
hcfmusp.origem.wosWOS:001182736500001
hcfmusp.publisher.cityBASELeng
hcfmusp.publisher.countrySWITZERLANDeng
hcfmusp.relation.referenceANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499eng
hcfmusp.relation.reference[Anonymous], 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet, V352, P837, DOI [10.1016/S0140-6736(98)07019-6, DOI 10.1016/S0140-6736(98)07019-6]eng
hcfmusp.relation.referenceBASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178eng
hcfmusp.relation.referenceCeriello A, 2010, DIABETIC MED, V27, P862, DOI 10.1111/j.1464-5491.2010.02967.xeng
hcfmusp.relation.referenceCeriello A, 2009, J CLIN ENDOCR METAB, V94, P410, DOI 10.1210/jc.2008-1824eng
hcfmusp.relation.referenceChan PS, 2010, J DIABETES COMPLICAT, V24, P55, DOI 10.1016/j.jdiacomp.2008.10.002eng
hcfmusp.relation.referenceChen H, 2001, J Tongji Med Univ, V21, P68eng
hcfmusp.relation.referenceChen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368eng
hcfmusp.relation.referenceda Silva KS, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00723eng
hcfmusp.relation.referenceEl-Osta A, 2008, J EXP MED, V205, P2409, DOI 10.1084/jem.20081188eng
hcfmusp.relation.referenceFishman SL, 2018, MOL MED, V24, DOI 10.1186/s10020-018-0060-3eng
hcfmusp.relation.referenceGARFIN DE, 1990, METHOD ENZYMOL, V182, P425eng
hcfmusp.relation.referenceGomes DJ, 2016, J DIABETES COMPLICAT, V30, P1614, DOI 10.1016/j.jdiacomp.2016.07.001eng
hcfmusp.relation.referenceGubitosi-Klug RA, 2016, DIABETES CARE, V39, P686, DOI 10.2337/dc15-1990eng
hcfmusp.relation.referenceHAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182eng
hcfmusp.relation.referenceIborra RT, 2018, J DIABETES COMPLICAT, V32, P1, DOI 10.1016/j.jdiacomp.2017.09.012eng
hcfmusp.relation.referenceIMURA H, 1993, NEW ENGL J MED, V329, P683, DOI 10.1056/NEJM199309023291002eng
hcfmusp.relation.referenceIwai K, 2012, TRENDS CELL BIOL, V22, P355, DOI 10.1016/j.tcb.2012.04.001eng
hcfmusp.relation.referenceKhalid M, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12040542eng
hcfmusp.relation.referenceKLEIN D, 1995, BIOCHEM MOL BIOL INT, V36, P59eng
hcfmusp.relation.referenceKowluru RA, 2004, ACTA DIABETOL, V41, P194, DOI 10.1007/s00592-004-0165-8eng
hcfmusp.relation.referenceKowluru RA, 2004, J DIABETES COMPLICAT, V18, P282, DOI 10.1016/j.jdiacomp.2004.03.002eng
hcfmusp.relation.referenceKowluru RA, 2003, DIABETES, V52, P818, DOI 10.2337/diabetes.52.3.818eng
hcfmusp.relation.referenceKowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/21976eng
hcfmusp.relation.referenceLan KC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124418eng
hcfmusp.relation.referenceLi JF, 1997, J BIOL CHEM, V272, P16498, DOI 10.1074/jbc.272.26.16498eng
hcfmusp.relation.referenceLiu PQ, 2022, BIOMED PHARMACOTHER, V153, DOI 10.1016/j.biopha.2022.113513eng
hcfmusp.relation.referenceLivak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262eng
hcfmusp.relation.referenceLOWRY OH, 1951, J BIOL CHEM, V193, P265eng
hcfmusp.relation.referenceMachado-Lima A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197265eng
hcfmusp.relation.referenceMinanni CA, 2021, NUTRIENTS, V13, DOI 10.3390/nu13103633eng
hcfmusp.relation.referenceMitchell S, 2016, WIRES SYST BIOL MED, V8, P227, DOI 10.1002/wsbm.1331eng
hcfmusp.relation.referenceO'Carroll SJ, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0346-0eng
hcfmusp.relation.referenceOkuda LS, 2012, BBA-MOL CELL BIOL L, V1821, P1485, DOI 10.1016/j.bbalip.2012.08.011eng
hcfmusp.relation.referencePinto RS, 2022, DIABETES VASC DIS RE, V19, DOI 10.1177/14791641221085269eng
hcfmusp.relation.referencePinto DC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26482-6eng
hcfmusp.relation.referencePrantner D, 2020, FASEB J, V34, P15659, DOI 10.1096/fj.202002136Reng
hcfmusp.relation.referenceRomero-Calvo I, 2010, ANAL BIOCHEM, V401, P318, DOI 10.1016/j.ab.2010.02.036eng
hcfmusp.relation.referenceSakaguchi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023132eng
hcfmusp.relation.referenceSharma A, 2021, DIABETES, V70, P772, DOI 10.2337/db20-0357eng
hcfmusp.relation.referenceShen CY, 2020, MOLECULES, V25, DOI 10.3390/molecules25235591eng
hcfmusp.relation.referenceShin A, 2022, ANAL BIOANAL CHEM, V414, P4861, DOI 10.1007/s00216-022-04108-1eng
hcfmusp.relation.referenceSong N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02305eng
hcfmusp.relation.referenceVermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139eng
hcfmusp.relation.referenceWan LQ, 2022, INT J BIOL SCI, V18, P809, DOI 10.7150/ijbs.63219eng
hcfmusp.relation.referenceWu CH, 2002, MOL CELL ENDOCRINOL, V194, P9, DOI 10.1016/S0303-7207(02)00212-5eng
hcfmusp.relation.referenceXie JL, 2013, CELL SIGNAL, V25, P2185, DOI 10.1016/j.cellsig.2013.06.013eng
hcfmusp.relation.referenceYao YF, 2022, CARDIOVASC RES, V118, P196, DOI 10.1093/cvr/cvab013eng
hcfmusp.relation.referenceYu H, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00312-6eng
hcfmusp.relation.referenceZawada A, 2022, NUTRIENTS, V14, DOI 10.3390/nu14193982eng
hcfmusp.relation.referenceZgutka K, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24129881eng
hcfmusp.relation.referenceZhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6eng
hcfmusp.relation.referenceZhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-Xeng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicationf73e2bd9-2ccd-4ef9-a3fc-b4d0531cf21a
relation.isAuthorOfPublication1066747e-87bf-4e97-8cc0-93c6df558403
relation.isAuthorOfPublicationc897fcfa-f89f-4c49-b360-625962bb4242
relation.isAuthorOfPublication5b7d6895-10fa-4a32-bd98-f6c9612baf15
relation.isAuthorOfPublicationfb60ed17-4a4a-41cd-b8f4-1bf7b2aa34b6
relation.isAuthorOfPublication14c896aa-f0a4-4867-859f-584e13ca81d4
relation.isAuthorOfPublicationa816ae7a-8943-42d1-81f4-eeb39f544483
relation.isAuthorOfPublication18ebd8cf-6b7b-4124-bc0a-853c2d1198d1
relation.isAuthorOfPublicationa56f4aa4-4cfe-4913-8499-32e6a25a1fe3
relation.isAuthorOfPublication5012dfbb-5b85-4e5c-95e8-a2abbf0d3b5a
relation.isAuthorOfPublication.latestForDiscoveryf73e2bd9-2ccd-4ef9-a3fc-b4d0531cf21a
Arquivos
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM